CDX2 and cancer: All these kinases displayed mutations in more than 6% of CDX2-suppressed colorectal cancers in the TCGA cohort, and some receptor tyrosine kinases, including EGFR, ERBB3, ERBB4, RET, ROS1, and ALK, showed even higher mutation rates in these cancers (Figure 1).